Authors

Timothy D. Lyon, MD is an Associate Professor of Urology and the Urology Residency Program Director at Mayo Clinic in Jacksonville, Florida.

Latest:

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO

Latest:

Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

Kimberly A. Spickes, CNP

Latest:

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Omar Alkharabsheh, MD

Latest:

Dr. Alkharabsheh on Remaining Challenges in High-Risk CLL

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.

Linda Perry, PA-C

Latest:

Using Multidisciplinary Care to Optimize Outcomes in GVHD

Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.

Sara Char, MD

Sara Char MD is a clinical fellow in Hematology and Oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital.

Latest:

Dr Char on the Association Between the Empirical Dietary Inflammatory Pattern and Survival Outcomes in Stage III Colon Cancer

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

Christopher Flowers, MD

Latest:

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.

Claire Harrison, MD, FRCP, FRCPath

Claire Harrison, MD, FRCP, FRCPath, is a professor at Guy’s and St. Thomas’ Hospital.

Latest:

Dr Harrison on Factors Influencing Patient Prognosis and Treatment Selection in Myelofibrosis

Claire Harrison, MD, FRCP, FRCPath, discusses factors informing treatment selection for patients with myelofibrosis.

Sarah Donahue, MPH, NP, AOCNP

Latest:

Novel Clinical Trials With ADCs in Gastric Cancer

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.

Ian Rabinowitz, MD

Latest:

Camidge and Rabinowitz Reflect on Finding Strength and Inspiration on Both Sides of a Cancer Diagnosis

Drs Camidge and Rabinowitz discuss the balance between professional and personal life that Rabinowitz navigated when he was diagnosed with lung cancer.

Aurelie Garant, MD, UT Southwestern Medical Center

Latest:

Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Craig Cole, MD

Latest:

Putting Culturally Competent Care into Practice

Joseph Mikhael, MD, and Craig Cole, MD, close the program by sharing examples of times culturally competent care was paramount to the treatment of their patients.

Ilana Schlam, MD

Latest:

Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.

Ziad Hanhan, MD

Ziad Hanhan, MD, is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center, and chief of Thoracic Surgery at Riverview Medical Center

Latest:

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Fred Saab, MD, FRCS

Sandra Toogood

Latest:

Novel Frontline Combinations Influence Later-Line Treatment Strategies in SCLC

While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.

Valeria Santini, MD

Latest:

Unmet Needs and Future of Lower-Risk MDS

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

Bhagirathbhai Dholaria, MBBS

Bhagirathbhai Dholaria, MBBS, is an associate professor of medicine in the Division of Hematology and Oncology, of the Department of Medicine, at Vanderbilt University Medical Center.

Latest:

Dr Dholaria on the Mechanism of Action of P-BCMA-ALLO1 in Multiple Myeloma

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Nicholas Wrigley

Latest:

Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCL

Using polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma.

Lubna N. Chaudhary, MD

Latest:

Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer

Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.